Clinical trials
Phase 3 Lupus Erythematosus, Systemic trials in Italy
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
32 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2004 | 1 |
| 2005 | 1 |
| 2006 | 1 |
| 2007 | 1 |
| 2008 | 1 |
| 2010 | 3 |
| 2011 | 2 |
| 2018 | 1 |
| 2019 | 1 |
| 2020 | 2 |
| 2021 | 4 |
| 2022 | 3 |
| 2023 | 3 |
| 2024 | 3 |
| 2026 | 4 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 11 |
| Active, not recruiting | 7 |
| Recruiting | 7 |
| Terminated | 4 |
| Enrolling by invitation | 2 |
| Withdrawn | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| UCB Pharma | 5 |
| Novartis Pharmaceuticals | 4 |
| AstraZeneca | 3 |
| Eli Lilly and Company | 3 |
| UCB Biopharma SRL | 3 |
| Biogen | 2 |
| EMD Serono Research & Development Institute, Inc. | 2 |
| Human Genome Sciences Inc., a GSK Company | 2 |
| La Jolla Pharmaceutical Company | 2 |
| AbbVie | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Lupus Erythematosus, Systemic | 32 |
| Autoimmune Diseases | 6 |
| Lupus Nephritis | 5 |
| Immune System Diseases | 4 |
| Connective Tissue Diseases | 3 |
| Lupus Erythematosus, Cutaneous | 2 |
| Lupus Erythematosus, Discoid | 2 |
| Nephritis | 2 |
| Arthritis, Juvenile | 1 |
| Macrophage Activation Syndrome | 1 |
Trials
Showing 1 to 25 of 32. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.